The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium

Ziekenhuis Oost-Limburg1 site in 1 country385 target enrollmentMarch 1, 2019

ConditionsNAFLD T2D Type 2 Diabetes Fatty Liver, Nonalcoholic

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: NAFLD
Sponsor: Ziekenhuis Oost-Limburg
Enrollment: 385
Locations: 1
Primary Endpoint: Prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients
Status: Active, not recruiting
Last Updated: 5 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).

Registry

clinicaltrials.gov

Start Date

March 1, 2019

End Date

November 1, 2026

Last Updated

5 months ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Ziekenhuis Oost-Limburg

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•≥ 18 years of age
•Having type 2 diabetes mellitus (T2DM)
•Written informed consent obtained

Exclusion Criteria

•Excessive alcohol use
•Exclusion of other causes of liver disease and secondary causes of steatosis

Outcomes

Primary Outcomes

Prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients

Time Frame: Baseline

To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients followed at the department of Endocrinology in Ziekenhuis Oost-Limburg (ZOL), Genk, Belgium by means of FibroScan measurements.